Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatostatin analog lanreotide in Merkel cell carcinoma
2014-001273-13Phase 2Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Aug 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in Merkel cell carcinoma (MCC), sponsored by CHU Grenoble Alpes. Started Aug 2015; status: completed.
02
Drugs
lanreotide
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2014-001273-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001273-13.